Oct 16, 2024
Eisai will request reconsideration of initial decision for lecanemab in Australia
Aug 22, 2024
Regarding rumors of an imminent approval of lecanemab in Great Britain: BioArctic
Aug 22, 2024
Leqembi (lecanemab) authorized for early Alzheimer's disease in Great Britain
Jul 30, 2024
Long-term lecanemab data show increased patient benefit with maintained safety profile
Jul 26, 2024
Eisai will seek re-examination of CHMP opinion för lecanemab
Jul 26, 2024
CHMP has adopted a negative opinion on lecanemab for the EU
Jul 23, 2024
Long-term treatment data for lecanemab to be presented at AAIC 2024
Jun 09, 2024
FDA accepts filing of Leqembi® (lecanemab-irmb) sBLA for IV maintenance dosing for the treatment of early Alzheimer's Disease
May 14, 2024
Eisai projects Leqembi® revenue to total JPY 56.5 billion for fiscal year 2024 (April 2024 - March 2025)
May 14, 2024
Eisai initiates rolling Biologics License Application to US FDA for Leqembi® (lecanemab-irmb) for subcutaneous maintenance dosing
Apr 24, 2024
Leqembi® revenue totaled JPY 2.83 billion in the first quarter 2024
Apr 20, 2024
BioArctic and Eisai sign research evaluation agreement regarding BAN2802
Apr 10, 2024
BioArctic's focus on Sustainable Innovation qualifies company for new ESG Responsibility Index at Nasdaq Stockholm
Mar 31, 2024
Submission of Leqembi® (lecanemab-irmb) sBLA for IV maintenance dosing for the treatment of early Alzheimer's disease to the U.S. FDA completed
Mar 19, 2024
BioArctic: Professor Lars Lannfelt, awarded Fondation Recherche Alzheimer's European Grand Prix for his contributions to science and treatment of Alzheimer's disease
Mar 07, 2024
BioArctic's partner Eisai presents updated sales simulation for Leqembi® at its annual press conference
Feb 29, 2024
BioArctic: Latest data on lecanemab to be presented at the 2024 AD/PD(TM) congress
Feb 05, 2024
Sales of Leqembi® totaled 1.1 billion yen in the fourth quarter 2023
Jan 11, 2024
The European Medicines Agency's Scientific Advisory Group (SAG) to discuss the Marketing Authorisation Application for lecanemab: BioArctic
Jan 09, 2024
Leqembi® approved for the treatment of Alzheimer's disease in China